Alaunos Therapeutics (TCRT) Cash from Operations (2016 - 2025)
Historic Cash from Operations for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$844000.0.
- Alaunos Therapeutics' Cash from Operations fell 806.66% to -$844000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year increase of 7527.2%. This contributed to the annual value of -$5.0 million for FY2024, which is 8350.81% up from last year.
- Latest data reveals that Alaunos Therapeutics reported Cash from Operations of -$844000.0 as of Q3 2025, which was down 806.66% from -$701000.0 recorded in Q2 2025.
- Alaunos Therapeutics' Cash from Operations' 5-year high stood at -$592000.0 during Q4 2024, with a 5-year trough of -$21.5 million in Q2 2021.
- In the last 5 years, Alaunos Therapeutics' Cash from Operations had a median value of -$7.0 million in 2023 and averaged -$6.7 million.
- Per our database at Business Quant, Alaunos Therapeutics' Cash from Operations crashed by 5458.31% in 2021 and then soared by 9198.38% in 2024.
- Alaunos Therapeutics' Cash from Operations (Quarter) stood at -$15.1 million in 2021, then surged by 52.86% to -$7.1 million in 2022, then fell by 3.58% to -$7.4 million in 2023, then skyrocketed by 91.98% to -$592000.0 in 2024, then crashed by 42.57% to -$844000.0 in 2025.
- Its last three reported values are -$844000.0 in Q3 2025, -$701000.0 for Q2 2025, and -$772000.0 during Q1 2025.